Search Site
Home >> Signaling Pathways >> Proteases/Proteasome >> HIV Protease >> Amprenavir (agenerase)
Related Products
Amprenavir (agenerase)HIV-1 protease inhibitor

Amprenavir (agenerase)

Catalog No. A8201
Size Price Stock Qty
Evaluation Sample $28.00 In stock
5mg $40.00 In stock
50mg $260.00 In stock

Tel: +1-832-696-8203

Email: sales@apexbt.com

Worldwide Distributors

Sample solution is provided at 25 µL, 10mM.

Quality Control

Chemical structure

Amprenavir(agenerase)

Related Biological Data

Amprenavir(agenerase)

Related Biological Data

Amprenavir(agenerase)

Biological Activity

Description Amprenavir is an inhibitor of HIV protease with IC50 of 14.6 ng/mL in wild-type HIV isolates.
Targets HIV Protease          
IC50            

Amprenavir (agenerase) Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Amprenavir (agenerase) Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 161814-49-9 SDF Download SDF
Chemical Name [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
Canonical SMILES CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N
Formula C25H35N3O6S M.Wt 505.63
Solubility Soluble in DMSO > 10 mM Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

Background

Amprenavir (agenerase), an N,N-disubstituted hydroxyethylamino sulfonamide, is a novel inhibitor of human immunodeficiency virus type 1 (HIV-1) protease that potently inhibits the activity of HIV-1 protease with a value of 50% inhibition concentration IC50 of 0.6 nM and also weakly inhibits HIV-2 protease with IC50 value of 19 nM. Amprenavir binds to the catalytic aspartate residues of the HIV-1 protease and hence inhibits the processing of the gag and gag-pol polyprotein precursors, which cleave to yield structural proteins and replication enzymes of HIV, resulting in immature and noninfectious viral particles. Amprenavir has been effectively used for the treatment of HIV disease in patients with primary HIV infection.

Reference

Fung HB, Kirschenbaum HL, Hameed R. Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. Clin Ther. 2000 May;22(5):549-72.